Devita, Hellman, and Rosenberg's Cancer

LWBK1006-40 LWW-Govindan-Review December 12, 2011 20:33

Chapter 40•Treatment of Metastatic Cancer 511

Question 40.10. All of the following are TRUE about intraperitoneal chemotherapy,

EXCEPT:

A. Achieves high peritoneal concentration of chemotherapy, while min-

imizing systemic absorption and systemic toxicity.

B. Choice of drugs is determined by the chemosensitivity of the target

cancer and peritoneal pharmacokinetics.

C. Hyperthermia can enhance the cytotoxicity of intraperitoneal

chemotherapy.

D. Post-surgical residual tumor nodules’ size does not determine effective

tumor absorption of chemotherapy.

Question 40.11. Which of the following factors have prognostic significance in patients

with colorectal cancer, who undergo ablative therapy of hepatic meta-

stases?

A. Low pretreatment CEA levels

B. Diameter of largest lesion<3cm

C. No extrahepatic disease

D. All of the above

Question 40.12. All of the following statements about radionuclide treatment of bone

metastases are true, EXCEPT:

A. Strontium-89 and Samarium-153 are commonly used radionuclides

in the treatment of diffuse bone metastases.

B. For Strontium-89 the average time to clinical response is about 7 to

14 days with a median duration of action of 18 weeks.

C. Thrombocytopenia nadir is 1 to 2 weeks after treatment and com-

pletely recovers by 4 weeks.

D. Retreatment is possible for both Strontium-89 and Samarium-153

after an interval of 10 to 12 weeks and 6 to 10 weeks, respectively.

Question 40.13. All of the following statements are correct about radiosensitizers in brain

metastases treatment, EXCEPT:

A. Motexafin gadolinium (MGd) is a redox mediator that selectively

targets tumor cells and decreases local oxygen consumption.

B. In patients with brain metastases MGd use with WBRT did not

increase median survival or median time to neurologic progression.

C. In patients with non-small cell lung cancer and brain metastases, use

of MGd with WBRT was found to improve median time to neurologic

progression.

D. Use of RSR13, an allosteric modifier of hemoglobin that facilitates

O 2 release, along with WBRT in patients with breast cancer and

brain metastases was not associated with improved median survival

compared with WBRT alone.